Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients

T. Yoshihama, Tatsuyuki Chiyoda, Fumio Kataoka, Hiroyuki Nomura, Y. Iguchi, S. Hashimoto, Wataru Yamagami, Eiichirou Tominaga, N. Susumu, H. Tsuda, Daisuke Aoki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third-line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. Materials and Methods: The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. Results: The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8%, 0%, 0%, 43.8% and 15.7%, 50%, 66.7%, and 93.8%, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256;p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. Conclusions: TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.

Original languageEnglish
Pages (from-to)424-427
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume36
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Ovarian Neoplasms
Drug Therapy
Therapeutics
Survival
Carboplatin
Paclitaxel
Medical Records

Keywords

  • Epithelial ovarian cancer
  • Recurrent ovarian cancer
  • Third-line chemotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients. / Yoshihama, T.; Chiyoda, Tatsuyuki; Kataoka, Fumio; Nomura, Hiroyuki; Iguchi, Y.; Hashimoto, S.; Yamagami, Wataru; Tominaga, Eiichirou; Susumu, N.; Tsuda, H.; Aoki, Daisuke.

In: European Journal of Gynaecological Oncology, Vol. 36, No. 4, 2015, p. 424-427.

Research output: Contribution to journalArticle

@article{cf65e2ff9ce749bb9b6e2ab014d26786,
title = "Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients",
abstract = "Objective: Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third-line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. Materials and Methods: The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. Results: The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8{\%}, 0{\%}, 0{\%}, 43.8{\%} and 15.7{\%}, 50{\%}, 66.7{\%}, and 93.8{\%}, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256;p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. Conclusions: TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.",
keywords = "Epithelial ovarian cancer, Recurrent ovarian cancer, Third-line chemotherapy",
author = "T. Yoshihama and Tatsuyuki Chiyoda and Fumio Kataoka and Hiroyuki Nomura and Y. Iguchi and S. Hashimoto and Wataru Yamagami and Eiichirou Tominaga and N. Susumu and H. Tsuda and Daisuke Aoki",
year = "2015",
doi = "10.12892/ejgo2646.2015",
language = "English",
volume = "36",
pages = "424--427",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "4",

}

TY - JOUR

T1 - Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients

AU - Yoshihama, T.

AU - Chiyoda, Tatsuyuki

AU - Kataoka, Fumio

AU - Nomura, Hiroyuki

AU - Iguchi, Y.

AU - Hashimoto, S.

AU - Yamagami, Wataru

AU - Tominaga, Eiichirou

AU - Susumu, N.

AU - Tsuda, H.

AU - Aoki, Daisuke

PY - 2015

Y1 - 2015

N2 - Objective: Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third-line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. Materials and Methods: The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. Results: The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8%, 0%, 0%, 43.8% and 15.7%, 50%, 66.7%, and 93.8%, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256;p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. Conclusions: TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.

AB - Objective: Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third-line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. Materials and Methods: The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. Results: The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8%, 0%, 0%, 43.8% and 15.7%, 50%, 66.7%, and 93.8%, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256;p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. Conclusions: TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.

KW - Epithelial ovarian cancer

KW - Recurrent ovarian cancer

KW - Third-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84938597440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938597440&partnerID=8YFLogxK

U2 - 10.12892/ejgo2646.2015

DO - 10.12892/ejgo2646.2015

M3 - Article

VL - 36

SP - 424

EP - 427

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 4

ER -